Listed Medicine Compliance Reports – June 2026 Update

TGA

We’ve updated the Listed Medicine Compliance Reports database with the results of compliance reviews covering 13 listed medicines, including:

  • medicines reviewed to check whether they meet stability requirements
  • medicines reviewed to check evidence to support health claims about exercise performance
  • medicines with non-permitted health claims about:
    • nicotinamide adenine dinucleotide (NAD, NAD+, NADH) or nicotinamide mononucleotide (NMN),
    • fertility, preconception health and use by postpartum and breastfeeding women,
    • arthritis, osteoarthritis, irritable bowel syndrome, stomach ulcers, balancing cholesterol levels, autoimmune skin conditions, psoriasis, eczema, and rosacea.

Following the reviews, 8 of these medicines have been cancelled from the Australian Register of Therapeutic Goods (ARTG) and are no longer permitted to be supplied.

/Public Release. View in full here.